Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Depreciation & Amortization (CF): 2018-2024

Historic Depreciation & Amortization (CF) for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to $13.6 million.

  • Allogene Therapeutics' Depreciation & Amortization (CF) fell 3.43% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year decrease of 9.72%. This contributed to the annual value of $13.6 million for FY2024, which is 3.95% down from last year.
  • Allogene Therapeutics' Depreciation & Amortization (CF) amounted to $13.6 million in FY2024, which was down 3.95% from $14.2 million recorded in FY2023.
  • Allogene Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $14.3 million during FY2022, with a 5-year trough of $7.4 million in FY2020.
  • Over the past 3 years, Allogene Therapeutics' median Depreciation & Amortization (CF) value was $14.2 million (recorded in 2023), while the average stood at $14.0 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Depreciation & Amortization (CF) spiked by 68.06% in 2020, and later decreased by 3.95% in 2024.
  • Allogene Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $7.4 million in 2020, then soared by 40.61% to $10.5 million in 2021, then spiked by 36.74% to $14.3 million in 2022, then fell by 0.66% to $14.2 million in 2023, then fell by 3.95% to $13.6 million in 2024.